Deciphera Pharma rises after Europe approves tumor drug

Deciphera Pharmaceuticals

22/11/2021 13:20

** Drugmaker  DCPH.O  up 5.5% at $8.97 premarket
    ** European Commission approves co’s drug Qinlock for
treating adults with a type of advanced tumor that occurs in the
gastrointestinal tract  urn:newsml:reuters.com:*:nBw4FMgKda
    ** The decision is applicable to all 27 European Union
member states plus Iceland, Norway, and Liechtenstein
    ** The approval was based on a late-stage study that showed
a meaningful benefit in controlling disease and overall survival
in patients who had not responded positively to earlier
treatments 
    ** Qinlock works by limiting the activities of certain
cancer causing proteins
    ** Up to Friday's close, stock had fallen ~85% YTD 
    
    

 (Reporting by Oishee Majumdar)
 ((oishee.majumdar@thomsonreuters.com;))